• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AbCellera Announces Resignation of Board Member

    2/23/24 4:30:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABCL alert in real time by email

    AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024.

    "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission."

    Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Directors.

    "On behalf of the members of our board and management, I express our deep appreciation for Peter's contributions," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "I would also like to personally thank Peter for his mentorship over the past three years. It has been a great privilege to learn from him."

    Mr. Thiel did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Effective upon Mr. Thiel's resignation as a director, the size of the Company's Board of Directors will be reduced from six to five directors.

    About AbCellera Biologics Inc.

    AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

    AbCellera Forward-Looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240223923459/en/

    Get the next $ABCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    7/7/2026$11.00Hold → Buy
    The Benchmark Company
    5/5/2026$7.00Overweight
    Cantor Fitzgerald
    11/7/2025$4.00Outperform → Market Perform
    Leerink Partners
    7/7/2025$5.00Outperform
    Leerink Partners
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    More analyst ratings

    $ABCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Montalbano John S. bought $95,400 worth of shares (20,000 units at $4.77), increasing direct ownership by 9% to 241,000 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    5/18/26 12:09:44 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Thermopylae Holdings Ltd. bought $130,720 worth of shares (38,000 units at $3.44), increasing direct ownership by 0.07% to 56,134,097 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/2/26 2:16:40 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Thermopylae Holdings Ltd. bought $580,284 worth of shares (177,457 units at $3.27), increasing direct ownership by 0.32% to 56,096,097 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    2/27/26 4:20:01 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    SEC Filings

    View All

    AbCellera Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    7/6/26 2:53:55 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    6/17/26 12:38:25 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    6/12/26 12:12:02 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

    Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

    7/15/26 8:45:00 AM ET
    $ABCL
    $ABSI
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Semiconductors

    AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

    AbCellera (NASDAQ:ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For m

    7/7/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Appoints Dr. Lynn Seely to its Board of Directors

    AbCellera (NASDAQ:ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. "Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and women’s health. I am pleased to welcome her to AbCellera’s Board of Directors and look forward to having her on our team," said Carl Hansen, Ph.D., founder and CEO of AbCellera. Dr. Seely’s experience as a biopharmaceutical executive and board member includes an extensive background in strategic, clinical, and commercial execution, which are highly relevant to AbCellera's work in discovering and developing impactful a

    7/6/26 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Seely Lynn

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    7/6/26 6:20:50 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Seely Lynn

    3 - AbCellera Biologics Inc. (0001703057) (Issuer)

    7/6/26 6:15:08 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sandor Victor

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    7/6/26 6:04:55 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbCellera Biologics upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $11.00

    7/7/26 8:38:28 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on AbCellera Biologics with a new price target

    Cantor Fitzgerald initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $7.00

    5/5/26 7:02:58 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AbCellera Biologics from Outperform to Market Perform and set a new price target of $4.00

    11/7/25 8:27:29 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Leadership Updates

    Live Leadership Updates

    View All

    AbCellera Appoints Dr. Lynn Seely to its Board of Directors

    AbCellera (NASDAQ:ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. "Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and women’s health. I am pleased to welcome her to AbCellera’s Board of Directors and look forward to having her on our team," said Carl Hansen, Ph.D., founder and CEO of AbCellera. Dr. Seely’s experience as a biopharmaceutical executive and board member includes an extensive background in strategic, clinical, and commercial execution, which are highly relevant to AbCellera's work in discovering and developing impactful a

    7/6/26 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Appoints Dr. Victor Sandor to its Board of Directors

    AbCellera (NASDAQ:ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. "Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "I am pleased to welcome Dr. Sandor to AbCellera's Board of Directors and look forward to working with him." Before its acquisition by Pfizer Inc., Dr. Sandor served as Chief Medical Officer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array

    6/5/26 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Appoints Dr. Stephen Quake to its Board of Directors

    AbCellera (NASDAQ:ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., fo

    11/10/25 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Financials

    Live finance-specific insights

    View All

    As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

    Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

    7/15/26 8:45:00 AM ET
    $ABCL
    $ABSI
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Semiconductors

    AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

    AbCellera (NASDAQ:ABCL) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For m

    7/7/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

    ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. Ended Q1 2026 with total available liquidity of approximately $655 million. AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635. ABCL635 is a potential first-in-class antibody targeting the neurokinin 3 receptor (NK3R) for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dol

    5/11/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    11/14/24 4:11:49 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AbCellera Biologics Inc.

    SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

    2/14/24 4:21:54 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    2/13/24 5:01:32 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care